GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead

GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead

Source: 
Fierce Biotech
snippet: 

GlaxoSmithKline is making its first major foray into treating the fatty liver condition known as nonalcoholic steatohepatitis (NASH) as it pens a $1 billion asset pact with Arrowhead Pharmaceuticals.

The deal centers on Arrowhead’s experimental early clinical-stage RNAi therapy ARO-HSD, which is targeting HSD17B13, a member of the hydroxysteroid dehydrogenase family involved in the metabolism of hormones, fatty acids and bile acids, with the focus squarely on NASH.